6th Annual Project & Portfolio Management in the Pharmaceutical Industry

Jacob Fleming Conferences28 - 29 September 2010, Milan, Italy.
After 5 successful annuals and the industry feedback, Jacob Fleming Conferences is bringing a well-balanced program full of real life case studies on major achievements in Project & Portfolio Management Approaches established across leading Pharma companies.

Testimonials
"Good balance of speakers, great learning experience and excellent chairman!"
Director Research Project Management, MedImmune, UK

"Very high-quality & influential speakers."
Portfolio Director, AstraZeneca, UK

"Very practical, inspiring and high-level agenda. Very good conclusions from the chairman."
Senior Portfolio Manager, GlaxoSmithKline, Belgium

Expert Advisors
Head of Discovery Research, Roche, Switzerland
Vice President Portfolio Management, Strategic Planning, Bayer Schering Pharma, Germany
Vice President Project Management R&D, Amgen, USA
Scientific Vice President, Novo Nordisk, Denmark
Head R&D Portfolio Management, UCB, UK
Executive Vice President & Chief Scientific Officer, Ipsen, France
Executive Vice President Research & Development, Nycomed, Germany

Key speakers
Vice President Special Operations, Worldwide Research Centers of Emphasis, Pfizer, UK
Global Head Portfolio Management & Reporting, Sanofi Aventis, France
Head Global Project Management, Abbott, Germany
Global Head of Portfolio Management & Interfaces Discovery Research and Oncology, MerckSerono, Switzerland
Head Portfolio Management, Bayer Schering Pharma, Germany
Vice President Research, Lundbeck, Denmark
Senior Project Leader Cancer Immunotherapeutics, GSK Biologicals, Belgium

Key topics

  • Explore the ways how leading Pharma companies develop their portfolios to add value to key stakeholders
  • Trends in portfolio offerings – more for physicians, payers or patients?
  • The impact of current payer-driven environment and cost-containment initiatives on managing R&D projects
  • Achieving a balanced, rich & varied portfolio in a competitive and limited resources environment
  • Innovative approaches to managing Discovery Projects
  • Project Management in Late stage Development Projects
  • Prioritization and decision analysis tools –decision making on innovation
  • Balancing the risks in Project & Portfolio Management - Risk Management in PPM
  • Enhancing the innovation & strong portfolios through R&D collaborations and M&A – the role of alliance management & business development

Who should attend
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Portfolio Management, Project Management, Pharmaceutical Development, R&D, Strategic Planning & Decision, Strategy & Portfolio Analysis, Portfolio Selection, Decision Analysis.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6thPPM?partner=worldpharmanewsPPM

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche purchases shares in tender offer for Ignyta…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares v...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]